An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants

Mark Terence P. Mujer, Manoj P. Rai, Varunsiri Atti, Ian Limuel Dimaandal, Abigail S. Chan, Shiva Shrotriya, Krishna Gundabolu, Prajwal Dhakal

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor dabigatran and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban. NOACs have several benefits over warfarin, including faster time to the achieve effect, rapid onset of action, fewer documented food and drug interactions, lack of need for routine INR monitoring, and improved patient satisfaction. Local hemostatic measures, supportive care, and withholding the next NOAC dose are usually sufficient to achieve hemostasis among patients presenting with minor bleeding. The administration of reversal agents should be considered in patients on NOAC's with major bleeding manifestations (life-threatening bleeding, or major uncontrolled bleeding), or those who require rapid anticoagulant reversal for an emergent surgical procedure. The Food and Drug Administration (FDA) has approved two reversal agents for NOACs: idarucizumab for dabigatran and andexanet alfa for apixaban and rivaroxaban. The American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) have released an updated guideline for the management of patients with atrial fibrillation that provides indications for the use of these reversal agents. In addition, the final results of the ANNEXA-4 study that evaluated the efficacy and safety of andexanet alfa were recently published. Several agents are in different phases of clinical trials, and among them, ciraparantag has shown promising results. However, their higher cost and limited availability remains a concern. Here, we provide a brief review of the available reversal agents for NOACs (nonspecific and specific), recent updates on reversal strategies, lab parameters (including point-of-care tests), NOAC resumption, and agents in development.

Original languageEnglish (US)
Article number7636104
JournalAdvances in Hematology
Volume2020
DOIs
StatePublished - 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants'. Together they form a unique fingerprint.

  • Cite this

    Mujer, M. T. P., Rai, M. P., Atti, V., Dimaandal, I. L., Chan, A. S., Shrotriya, S., Gundabolu, K., & Dhakal, P. (2020). An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants. Advances in Hematology, 2020, [7636104]. https://doi.org/10.1155/2020/7636104